Summit Therapeutics SMMT
NASDAQ SMMT
$16.89 -0.94 (-5.30%)
As of: Nov 11, 2026 · 2:34 PM EST

Summit Therapeutics (SMMT) Non-Current Deferred Revenue (2019 - 2021)

Updated

Summit Therapeutics (SMMT) recorded Non-Current Deferred Revenue of $365,000 in Q2 2021, down 4.7% from the prior quarter.

Analysis

Summit Therapeutics (SMMT) Non-Current Deferred Revenue (2019 - 2021) Analysis & Trends

At the end of FY2020, Summit Therapeutics reported Non-Current Deferred Revenue of $569,000, up 15.4% from FY2019.

  • Across earlier years, Non-Current Deferred Revenue came in at $493,000 in FY2019.
  • Per Business Quant, the preceding three quarters came in at $383,000 (Q1 2021), $569,000 (Q4 2020) and $715,000 (Q3 2020).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Summit Therapeutics 14.26 Bn 11.63 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2021 365,000.00
Mar 31, 2021 383,000.00
Dec 31, 2020 569,000.00
Sep 30, 2020 715,000.00
Mar 31, 2020 -2.14 Mn
Dec 31, 2019 493,000.00
Oct 31, 2019 -483,814.81
Jul 31, 2019 -3.83 Mn
Jan 31, 2019 -4.43 Mn
API Access

Summit Therapeutics Non-Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-deffered-revenue&ticker=SMMT&period=max&api_key=YOUR_API_KEY